Rein Therapeutics Inc (RNTX)

$0.79 +0.00 (0.20%)
Market Cap 68.32M
Revenue (ttm) 0.00
Net Income (ttm) -49.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,488,700
Avg Vol 524,066
Day's Range N/A - N/A
Shares Out 86.27M
Stochastic %K 29%
Beta 1.39
Analysts Sell
Price Target $6.00

Company Profile

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 737 802 1989
Address:
12407 N. Mopac Expy., Suite 250 #390, Austin, United States
TW_Research
TW_Research Aug. 20 at 11:47 PM
$RNTX Enrollment going great. Stock not so much. Anyone have intelligent thoughts as to why the stock can’t catch a bid?
0 · Reply
Dont_Forget_The_Dates
Dont_Forget_The_Dates Aug. 20 at 7:35 PM
$RNTX https://www.sec.gov/Archives/edgar/data/1940272/000110465926097425/xslSCHEDULE_13G_X02/primary_doc.xml
0 · Reply
notreload_ai
notreload_ai Aug. 20 at 3:36 PM
$RNTX receives FDA Fast Track for LTI-03 in idiopathic pulmonary fibrosis. Phase 2 RENEW trial underway; interim data expected in H2 2026. https://notreload.xyz/xy/rntx-receives-fda-fast-track-for-lti-03-in-ipf/
1 · Reply
hafsaw
hafsaw Aug. 20 at 2:16 PM
$RNTX Nothing happend
1 · Reply
SannieVerraderlijk
SannieVerraderlijk Aug. 20 at 12:38 PM
$RNTX https://x.com/Rein_Tx/status/2090415301561069694?s=20
0 · Reply
SouthHaus
SouthHaus Aug. 20 at 12:20 PM
$RNTX Just stuck a toe in here.
1 · Reply
Jozue98
Jozue98 Aug. 20 at 12:12 PM
$RNTX i expected a big jump on this
0 · Reply
premarketmaker
premarketmaker Aug. 20 at 12:06 PM
$RNTX just hold - this is getting absorbed
0 · Reply
premarketmaker
premarketmaker Aug. 20 at 12:05 PM
$RNTX U.S. FDA Fast Track Designation Pulmonary Fibrosis -
0 · Reply
premarketmaker
premarketmaker Aug. 20 at 12:03 PM
$RNTX watch for move over $1.00
0 · Reply
Latest News on RNTX
Rein Therapeutics granted Fast Track designation for LTI-03

2026-08-20T12:05:59.000Z - 14 hours ago

Rein Therapeutics granted Fast Track designation for LTI-03

Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis

Aug 20, 2026, 8:00 AM EDT - 14 hours ago

Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics Slides: Corporate presentation

Aug 19, 2026, 8:00 AM EDT - 1 day ago

Rein Therapeutics Slides: Corporate presentation

Rein Therapeutics Quarterly report: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 6 days ago

Rein Therapeutics Quarterly report: Q2 2026

Rein Therapeutics Earnings release: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 6 days ago

Rein Therapeutics Earnings release: Q2 2026

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 14, 2026, 6:44 AM EDT - 6 days ago

Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications

Aug 4, 2026, 8:00 AM EDT - 16 days ago

Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications

Rein Therapeutics announces RENEW clinical trial open for enrollment

2026-07-21T12:05:48.000Z - 4 weeks ago

Rein Therapeutics announces RENEW clinical trial open for enrollment

Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries

Jul 21, 2026, 8:00 AM EDT - 4 weeks ago

Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries

Rein Therapeutics Transcript: AGM 2026

Jul 20, 2026, 9:00 AM EDT - 4 weeks ago

Rein Therapeutics Transcript: AGM 2026

Maxim starts Rein Therapeutics at Buy amid de-risked LTI-03 program

2026-07-20T12:50:27.000Z - 4 weeks ago

Maxim starts Rein Therapeutics at Buy amid de-risked LTI-03 program

Rein Therapeutics initiated with a Buy at Maxim

2026-07-20T11:45:11.000Z - 4 weeks ago

Rein Therapeutics initiated with a Buy at Maxim

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

Jun 11, 2026, 8:00 AM EDT - 2 months ago

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom

Rein Therapeutics Proxy statement: Proxy filing

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Rein Therapeutics Proxy statement: Proxy filing

Rein Therapeutics Proxy statement: Proxy filing

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Rein Therapeutics Proxy statement: Proxy filing

Rein Therapeutics price target lowered to $8 from $10 at H.C. Wainwright

2026-06-01T10:00:14.000Z - 2 months ago

Rein Therapeutics price target lowered to $8 from $10 at H.C. Wainwright

Rein Therapeutics Proxy statement: Proxy filing

May 28, 2026, 8:00 AM EDT - 3 months ago

Rein Therapeutics Proxy statement: Proxy filing

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

May 18, 2026, 8:00 AM EDT - 3 months ago

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

Rein Therapeutics Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Rein Therapeutics Quarterly report: Q1 2026

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

Apr 30, 2026, 8:00 PM EDT - 4 months ago

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

Rein Therapeutics provides update on RENEW clinical trial

2026-04-29T14:52:11.000Z - 4 months ago

Rein Therapeutics provides update on RENEW clinical trial

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics files to sell 30M shares of common stock

2026-04-28T21:45:51.000Z - 4 months ago

Rein Therapeutics files to sell 30M shares of common stock

Rein Therapeutics Registration statement: Registration filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Rein Therapeutics Registration statement: Registration filing

Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright

2026-04-02T15:00:37.000Z - 5 months ago

Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright

Rein Therapeutics Annual report: Q4 2025

Mar 26, 2026, 7:00 AM EDT - 5 months ago

Rein Therapeutics Annual report: Q4 2025

Rein Therapeutics downgraded to Hold from Buy at Brookline

2026-01-21T14:20:17.000Z - 7 months ago

Rein Therapeutics downgraded to Hold from Buy at Brookline

Rein Therapeutics Slides: Corporate presentation

Jan 21, 2026, 7:00 AM EST - 7 months ago

Rein Therapeutics Slides: Corporate presentation

Rein Therapeutics receives orphan drug designation from EMA for LTI-03

2026-01-20T13:12:26.000Z - 7 months ago

Rein Therapeutics receives orphan drug designation from EMA for LTI-03

Rein Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 4:00 PM EST - 9 months ago

Rein Therapeutics Quarterly report: Q3 2025

Rein Therapeutics announces publication on LTI-03

2025-11-06T13:27:27.000Z - 10 months ago

Rein Therapeutics announces publication on LTI-03

Rein Therapeutics upgraded to Buy from Hold at Brookline

2025-11-03T17:55:07.000Z - 10 months ago

Rein Therapeutics upgraded to Buy from Hold at Brookline

Rein Therapeutics receives FDA clearance to resume Phase 2 trial of LTI-03

2025-11-03T12:36:11.000Z - 10 months ago

Rein Therapeutics receives FDA clearance to resume Phase 2 trial of LTI-03

Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03

2025-10-09T11:36:09.000Z - 11 months ago

Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Oct 9, 2025, 7:30 AM EDT - 11 months ago

Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics initiated with a Buy at H.C. Wainwright

2025-09-22T10:10:15.000Z - 11 months ago

Rein Therapeutics initiated with a Buy at H.C. Wainwright

Rein Therapeutics announces publication of data on LTI-03 in IPF

2025-09-17T11:35:19.000Z - 1 year ago

Rein Therapeutics announces publication of data on LTI-03 in IPF

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis

Sep 17, 2025, 7:30 AM EDT - 1 year ago

Rein Therapeutics Announces Publication of New Translational Data in iScience on Company's Novel Therapy for Idiopathic Pulmonary Fibrosis

Rein Therapeutics files to sell 10M shares of common stock for holders

2025-09-03T21:05:11.000Z - 1 year ago

Rein Therapeutics files to sell 10M shares of common stock for holders

Rein Therapeutics Registration statement: Registration Filing

Sep 3, 2025, 8:00 AM EDT - 1 year ago

Rein Therapeutics Registration statement: Registration Filing

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Aug 19, 2025, 8:00 AM EDT - 1 year ago

Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

Aug 14, 2025, 5:00 PM EDT - 1 year ago

Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025

Rein Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics Quarterly report: Q2 2025

Rein Therapeutics Transcript: AGM 2025

Jul 23, 2025, 9:00 AM EDT - 1 year ago

Rein Therapeutics Transcript: AGM 2025

Rein Therapeutics Proxy statement: Proxy Filing

Jul 11, 2025, 8:00 AM EDT - 1 year ago

Rein Therapeutics Proxy statement: Proxy Filing

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Jun 24, 2025, 10:11 AM EDT - 1 year ago

Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders

Rein Therapeutics Proxy statement: Proxy Filing

Jun 24, 2025, 8:00 AM EDT - 1 year ago

Rein Therapeutics Proxy statement: Proxy Filing

US FDA puts on hold Rein Therapeutics' lung disease drug trial

Jun 12, 2025, 5:18 PM EDT - 1 year ago

US FDA puts on hold Rein Therapeutics' lung disease drug trial

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

IQV

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

May 19, 2025, 4:51 PM EDT - 1 year ago

Rein Therapeutics Presents Two Posters at the American Thoracic Society 2025 International Conference

Rein Therapeutics Registration statement: Registration Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Rein Therapeutics Registration statement: Registration Filing

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 4:09 PM EDT - 1 year ago

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Rein Therapeutics Slides: Corporate presentation

May 15, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics Slides: Corporate presentation

Rein Therapeutics Earnings release: Q1 2025

May 15, 2025, 12:00 AM EDT - 1 year ago

Rein Therapeutics Earnings release: Q1 2025

Rein Therapeutics Quarterly report: Q1 2025

May 15, 2025, 12:00 AM EDT - 1 year ago

Rein Therapeutics Quarterly report: Q1 2025

Rein Therapeutics Proxy statement: Proxy Filing

May 12, 2025, 8:00 AM EDT - 1 year ago

Rein Therapeutics Proxy statement: Proxy Filing

Rein Therapeutics Proxy statement: Proxy Filing

May 12, 2025, 8:00 AM EDT - 1 year ago

Rein Therapeutics Proxy statement: Proxy Filing

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 12, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 12:00 PM EDT - 1 year ago

Rein Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

May 1, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Apr 30, 2025, 4:05 PM EDT - 1 year ago

Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Apr 28, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Apr 15, 2025, 7:00 AM EDT - 1 year ago

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Apr 7, 2025, 4:17 PM EDT - 1 year ago

Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

TW_Research
TW_Research Aug. 20 at 11:47 PM
$RNTX Enrollment going great. Stock not so much. Anyone have intelligent thoughts as to why the stock can’t catch a bid?
0 · Reply
Dont_Forget_The_Dates
Dont_Forget_The_Dates Aug. 20 at 7:35 PM
$RNTX https://www.sec.gov/Archives/edgar/data/1940272/000110465926097425/xslSCHEDULE_13G_X02/primary_doc.xml
0 · Reply
notreload_ai
notreload_ai Aug. 20 at 3:36 PM
$RNTX receives FDA Fast Track for LTI-03 in idiopathic pulmonary fibrosis. Phase 2 RENEW trial underway; interim data expected in H2 2026. https://notreload.xyz/xy/rntx-receives-fda-fast-track-for-lti-03-in-ipf/
1 · Reply
hafsaw
hafsaw Aug. 20 at 2:16 PM
$RNTX Nothing happend
1 · Reply
SannieVerraderlijk
SannieVerraderlijk Aug. 20 at 12:38 PM
$RNTX https://x.com/Rein_Tx/status/2090415301561069694?s=20
0 · Reply
SouthHaus
SouthHaus Aug. 20 at 12:20 PM
$RNTX Just stuck a toe in here.
1 · Reply
Jozue98
Jozue98 Aug. 20 at 12:12 PM
$RNTX i expected a big jump on this
0 · Reply
premarketmaker
premarketmaker Aug. 20 at 12:06 PM
$RNTX just hold - this is getting absorbed
0 · Reply
premarketmaker
premarketmaker Aug. 20 at 12:05 PM
$RNTX U.S. FDA Fast Track Designation Pulmonary Fibrosis -
0 · Reply
premarketmaker
premarketmaker Aug. 20 at 12:03 PM
$RNTX watch for move over $1.00
0 · Reply
JesterOfWallSt
JesterOfWallSt Aug. 20 at 12:02 PM
$RNTX 🔥🔥🔥 $STKH $BTCT.X $WETO
0 · Reply
premarketmaker
premarketmaker Aug. 20 at 12:02 PM
$RNTX Fast Track Designation Pulmonary like $MRNA
0 · Reply
Stock_Catcher
Stock_Catcher Aug. 20 at 12:00 PM
$RNTX Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
0 · Reply
wolfcyd3
wolfcyd3 Aug. 20 at 11:44 AM
$RNTX added
0 · Reply
MomentumWins
MomentumWins Aug. 20 at 2:04 AM
$RNTX next mrna type moves ahead … october some results expected
0 · Reply
rapture_iscoming
rapture_iscoming Aug. 19 at 1:50 PM
$MRNA next one to move like this is $RNTX
0 · Reply
SevenPhigs27
SevenPhigs27 Aug. 19 at 12:52 AM
$RNTX New 13G 4.5MM ADAR1 Capital Management, LLC
0 · Reply
SevenPhigs27
SevenPhigs27 Aug. 18 at 7:40 PM
$RNTX Added. Didn't expect this but I'll take it. GLTA
0 · Reply
SevenPhigs27
SevenPhigs27 Aug. 17 at 4:10 PM
$RNTX Expecting volume. Who knows. GLTA
0 · Reply
Kevingeorge
Kevingeorge Aug. 16 at 7:09 AM
$RNTX whats your pt?
3 · Reply
BrianWindsor
BrianWindsor Aug. 14 at 12:58 PM
$RNTX Q2 results are out. Phase 2 RENEW enrolling in all five planned countries, with 25% of planned enrollment reached. First clinical data in IPF patients published in Nature Communications after independent peer review. Closed an oversubscribed $57.5M offering that funds us through the trial. More detail in the video here. Earnings release link in comments below.
1 · Reply
Golfskier
Golfskier Aug. 12 at 2:40 PM
$RNTX well, these guys have until end of month to avoid a NAZ warning letter...definitely could apply for an extension but what an added hassle...ugh!
0 · Reply